A biomarker signature based on HDA, DHK-PGA2, and AFP showed great diagnostic efficacy in diagnosing T2DM(+) HCC from T2DM and other T2DM(+) cancers, including GC, PC, and CRC, suggesting its potential for clinical application. This evidence concerns the gene AFP and hepatocellular carcinoma.